For example, using an anti-HER2/HER3 dendritic cell vaccine in combination with Pembrolizumab (a PD-1 inhibitor) can significantly improve CNS response rates and progression-free survival in patients with HER2-positive breast cancer BM (112). Here, ERBB2 is linked to breast carcinoma.